Isolation of Peptide Transport System-6 from Brain Endothelial Cells: Therapeutic Effects with Antisense Inhibition in Alzheimer and Stroke Models
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
By isolating for the first time ever a peptide transporter from the blood—brain barrier (BBB) and developing an antisense that selectively targets the brain-to-blood efflux component, we were able to deliver a therapeutic concentration of the neurotrophic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) 27 to brain in animal models of Alzheimer's and stroke. Efflux pumps at the BBB are major causes of BBB impermeability to peptides. PACAP is neuroprotective in vitro in femtomole amounts, but brain uptake of PACAP27 is limited by an efflux component of peptide transport system-6 (PTS-6). Here, we characterized, isolated, and sequenced this component of PTS-6, identifying it as β-F1 ATPase, and colocalized it with PACAP27 on BBB endothelial cells. Antisenses targeting the BBB inhibited PACAP27 efflux, thus increasing brain uptake of PACAP27. Treatment with antisense +PACAP27 improved cognition in a mouse model of Alzheimer's disease and reduced infarct size after cerebral ischemia. This represents the first isolation from BBB tissue of a peptide transporter and shows that inhibition of peptide efflux pumps is a potential strategy for drug delivery to brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Murine tumor necrosis factor alpha is transported from blood to brain in the mouse
Gutierrez, E. G., Banks, W. A., & Kastin, A. J. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90027-v · Cited by 577 · cited 1×
“We used the capillary depletion method to determine whether the antisenses were taken up by the BBB (Triguero et al, 1990; Gutierrez et al, 1993).”
MethodSelf-citation
Cited by
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
“It may also be possible for them to use a peptide-specific transporter protein, directly inserted into the cell membrane in a similar manner to the solute transporters, which transfers them through the membrane (Kastin and Pan, 2003; Banks, 2004; Dogrukol-Ak et al., 2009).”
BackgroundNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Self-citationPituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery
Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B. K. C., Hashimoto, H., Galas, L., et al. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001370 · Cited by 1,058
Characteristics of Compounds that Cross the Blood-Brain Barrier
Banks, W. A. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s3 · Cited by 710
Self-citationRedzic, Z. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-3 · Cited by 418
Anatomy and physiology of the blood-brain barrier
Serlin, Y., Shelef, I., Knyazer, B., & Friedman, A. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.01.002 · Cited by 397
Strazielle, N., & Ghersi-Egea, J. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300518e · Cited by 263
Ramirez, S. H., Haskó, J., Skuba, A., Fan, S., Dykstra, H., McCormick, R., Reichenbach, N., Krizbai, I., Mahadevan, A., Zhang, M., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4628-11.2012 · Cited by 237
“Brain microvessels were isolated as described previously (Dogrukol-Ak et al., 2009), and lysates were prepared using the CelLytic-M reagent (Sigma).”
MethodDrug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Self-citationIntrathecal delivery of protein therapeutics to the brain: A critical reassessment
Calias, P., Banks, W. A., Begley, D., Scarpa, M., & Dickson, P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.009 · Cited by 175
“…that efflux of the neurotrophic peptide, pituitary adenylate cyclase-activating polypeptide 27, limits it accumulation in the brain and that inhibition of the efflux transporter allows intravenously administered peptide to accumulate in the brain to therapeutic levels (Dogrukol-Ak et al., 2009).”
Self-citationStaquicini, F. I., Ozawa, M. G., Moya, C. A., Driessen, W. H. P., Barbu, E. M., Nishimori, H., Soghomonyan, S., Flores, L. G., Liang, X., Paolillo, V., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44798 · Cited by 165
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Rhea, E. M., Salameh, T. S., Gray, S., Niu, J., Banks, W. A., & Tong, J. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.007 · Cited by 114
Self-citation
Metadata
- Authors
- Dogrukol-Ak, D., Kumar, V. B., Ryerse, J. S., Farr, S. A., Verma, S., Nonaka, N., Nakamachi, T., Ohtaki, H., Niehoff, M. L., Edwards, J. C., Shioda, S., Morley, J. E., & Banks, W. A.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2008-11-12
- Volume
- 29
- Issue
- 2
- Pages
- 411-422
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2059111801
- Cited by
- 82
- References
- 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.